Dr. Arvinder Singh Bir, MD

Dr. Bir practices at St. Mary's Regional Hospital in Grand Junction, Colorado, part of Intermountain Health.

Dr. Bir's NPI, 1417164898, was assigned on May 16, 2007. Dr. Bir holds West Virginia license 23182.

Dr. Bir's primary practice is St. Mary's Regional Hospital, at 2635 N 7th St, Grand Junction, CO 81501 in Mesa County. The practice phone is (970) 298-2260. Dr. Bir also practices at St. Mary's Medical Center, 2900 1st Ave, Huntington, WV 25702.

Dr. Bir's primary practice is St. Mary's Regional Hospital in Grand Junction, Colorado, part of Intermountain Health. Dr. Bir is also affiliated with St. Mary's Medical Center. The medical group on file is HIMG (Huntington Internal Medicine Group). Dmand AI also links Dr. Bir to 1 more hospital, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bir practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bir's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bir is licensed in West Virginia.

CMS data shows 2,310 Medicare services from Dr. Bir across 8 procedure codes in 2024, for 564 Medicare patients. Medicare paid $147,755 for them.

CMS counts 564 Medicare patients who saw Dr. Bir in 2024. The largest group is 75 to 84, with 225 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bir's median patient age at 74, with 57% women.

In 2024, Dr. Bir wrote 1,934 Medicare Part D claims for 352 patients. 80% of them were for generic drugs. CMS names the drug for 1,708 of them, across 53 drugs with 11 or more claims each, at $3,616,321 in total drug cost. In 2023, CMS named 1,528 claims across 47 drugs.

Dr. Bir accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Bir in 2024. Dr. Bir's most frequent co-authors are Damian Silbermins, MD, Matias Emanuel Valsecchi, MD and Mahmoud Youssef Abdallah, DO.

Dmand AI links Dr. Bir to 10 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Breast Diseases. SWOG Cancer Research Network sponsors the most, 7.

CMS Open Payments shows 1,557 general payments to Dr. Bir from 98 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $42,180.